Skip to content

D&A at other companies

LivaNova logo
LivaNovaLIVN
$8.3M+29.3%
ICU Medical logo
ICU MedicalICUI
$50.03M+1.2%
Edwards Lifesciences logo
Edwards LifesciencesEW
$40.9M+11.7%
United Therapeutics logo
United TherapeuticsUTHR
$22.6M+14.1%
OSI Systems logo
OSI SystemsOSIS
$9.52M-9.9%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s D&A?
TransMedics Group, Inc. (TMDX) reported D&A of $11.86M in Q1 2026.
How has TransMedics Group, Inc.'s D&A changed year-over-year?
TransMedics Group, Inc.'s D&A increased by 93.3% year-over-year, from $6.14M to $11.86M.
What is the long-term trend for TransMedics Group, Inc.'s D&A?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s D&A has grown at a 96.7% compound annual growth rate (CAGR), from $1.82M to $27.19M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.